Navigation Links
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Date:8/19/2007

e II trial and another milestone upon the dosing of the first patient in a Phase III trial for any use of the drug.

Myriad also reported data from two completed Phase 1 clinical trials of Azixa in a total of 66 patients, one in patients with refractory solid tumors that may also have had brain metastases and the other in patients with known brain metastases. The trials were designed to explore the safety and pharmacokinetics of Azixa and to find the maximum tolerated dose of the compound. Myriad reported that in the Phase 1 studies, Azixa appeared to have a biological effect on patients' metastases from many different primary tumors, including non-small-cell lung cancer, which is consistent with the mechanism of the drug candidate.

Azixa is one of two compounds in clinical trials discovered through EpiCept's Anti-cancer Screening Apoptosis Program (ASAP). EPC2407, a novel small molecule vascular disruption agent and apoptosis inducer for the treatment of cancer patients with advanced, solid tumors and lymphomas, is currently in Phase I clinical development by EpiCept. In July 2007, EpiCept announced the acceleration of the Phase I clinical trial, with results expected later this year. EpiCept expects to initiate a second Phase I efficacy trial for EPC2407 as a combination therapy in patients with well vascularized solid tumors and intends to choose multiple tumor targets for the compound's Phase II trials as the clinical profile from the ongoing monotherapy trial emerges.

About EpiCept's ASAP Technology

Cancer cells often exhibit unchecked growth caused by the disabling or absence of the natural process of programmed cell death, which is called apoptosis. Apoptosis is normally triggered to destroy a cell from within when it outlives its purpose or it is seriously damaged. One of the most promising approaches in the fight against cancer is to selectively induce apoptosis in cancer cells, thereby checking, and perhaps reversing, the improper ce
'/>"/>

SOURCE EpiCept Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , "The interface is the device," Nobel laureate ... properties to be found at the junctures where ... world of nanotechnology, the interfaces between layers of ... in such high-tech favorites as spintronics, high-temperature superconductors, ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider ... Limited, one of India’s top five pharmaceutical companies, has ... for high throughput solid form screening. , ... wide range of quality, affordable generic and branded formulations ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... $8.1 Million Financing in Connection With Acquisition ... Reverse Stock Split Planned for January 2008, LONDON, ... that the Company has:, - Signed an agreement to acquire ... Israel. The acquisition,is expected to close tomorrow. The initial consideration is ...
... Calif., Dec. 4 Sangamo BioSciences,Inc. (Nasdaq: SGMO ... community on its latest developments in several of its,therapeutic ... and Analyst Briefing that will be held from 4:30 ... The presentation will be webcast live and may be ...
... - Associated Forum Provides Resources for Healthcare Professionals, ... ... 4 The Liko-sponsored Safe Lifting,Portal today announced the launch of ... associated safe lifting,forum, called "Safe Lifters," will allow healthcare professionals to,discuss ...
Cached Biology Technology:Amarin Signs Agreement to Acquire Ester Neurosciences 2Amarin Signs Agreement to Acquire Ester Neurosciences 3Amarin Signs Agreement to Acquire Ester Neurosciences 4Amarin Signs Agreement to Acquire Ester Neurosciences 5Amarin Signs Agreement to Acquire Ester Neurosciences 6Amarin Signs Agreement to Acquire Ester Neurosciences 7Amarin Signs Agreement to Acquire Ester Neurosciences 8Amarin Signs Agreement to Acquire Ester Neurosciences 9Amarin Signs Agreement to Acquire Ester Neurosciences 10Amarin Signs Agreement to Acquire Ester Neurosciences 11Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2New Online 'Help Desk' Offers Safe Lifting Assistance to Healthcare Facilities 2
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... A Kansas State University engineer has developed ... remotely detects improvised explosive devices. The same technique ... Dunn, the Steven M. and Kay L. Theede ... and nuclear engineering, and his research team have ... underground or in car trunks. The distance detection ...
(Date:4/17/2014)... If a restaurant ... he can expect his premises to be trashed. Warnings like ... is enough to make restaurant owners pay up. Similarly, mafia-like ... in other birds, nests. If the host birds throw the ... destroying the entire nest. Consequently, it is beneficial for hosts ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... held secrets of the earth,s history locked in its icy ... on the environments that have been sealed beneath miles of ... from nine institutions including LSU have been funded ... Science Foundation, or NSF, to get to the bottom of ...
... the deadly superbug MRSAan infection-causing bacteria resistant to most common ... is making its way into hospitals, according to a study ... The new threat is easily picked up in ... the overall burden of MRSA within hospitals, the report found. ...
... that a common oral bacterium may exacerbate autoimmune disease. ... a Common Human Bacterium Represent a New Class of TLR2 ... issue of The American Journal of Pathology . ... the brain and spinal cord, affects nearly 1 in 700 ...
Cached Biology News:LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2
HSV 1 IgM...
Epstein-Barr Virus (EBV) (EBNA-1)...
X box-binding protein 1...
... Rabbit polyclonal to Neuron navigator 1 ( Abpromise ... Antigen: Synthetic peptide conjugated to KLH derived ... Mouse Neuron navigator 1. (Note: the amino ... available as ab32208 .) ...
Biology Products: